GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Debt-to-Asset

Eris Lifesciences (BOM:540596) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Debt-to-Asset?

Eris Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Eris Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Eris Lifesciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₹0 Mil.


Eris Lifesciences Debt-to-Asset Historical Data

The historical data trend for Eris Lifesciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Debt-to-Asset Chart

Eris Lifesciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.01 - 0.04 0.24

Eris Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.24 - 0.21 -

Competitive Comparison of Eris Lifesciences's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eris Lifesciences's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's Debt-to-Asset falls into.



Eris Lifesciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Eris Lifesciences's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1932.9 + 6834.21) / 36673.28
=0.24

Eris Lifesciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eris Lifesciences  (BOM:540596) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Eris Lifesciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Eris Lifesciences (BOM:540596) Business Description

Traded in Other Exchanges
Address
Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines